Comparative Pharmacology
Head-to-head clinical analysis: CALCIUM GLUCEPTATE versus SODIUM PHOSPHATES IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALCIUM GLUCEPTATE versus SODIUM PHOSPHATES IN PLASTIC CONTAINER.
CALCIUM GLUCEPTATE vs SODIUM PHOSPHATES IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium gluceptate is a calcium salt that dissociates to provide calcium ions, which are essential for various physiological processes including nerve conduction, muscle contraction, blood coagulation, and cardiac function. It acts as a calcium replenisher.
Sodium phosphates increase serum phosphate concentration, promoting renal excretion of calcium and phosphate, and inducing osmotic diarrhea to cleanse the colon.
IV: 2-4 mg/kg elemental calcium (5-10 mL of 0.45 mEq/mL solution) administered slowly over 10-20 minutes. May repeat if needed. Maximum dose: 20 mL per infusion.
Oral: 30-90 mL (equivalent to 3.75-11.25 g sodium phosphate) once daily, preferably in the morning, with a full glass of water. Dose may be increased up to 240 mL per day in divided doses. Rectal enema: 118 mL (monobasic sodium phosphate 19 g, dibasic sodium phosphate 7 g) as a single dose.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours (normal renal function); prolonged to 12-24 hours in renal impairment.
Terminal half-life of absorbed phosphate is approximately 0.5–1 hour in patients with normal renal function. Clinically, effects on serum phosphate are transient and depend on renal clearance.
Renal: >90% excreted unchanged in urine. Biliary/fecal: <5%.
Primarily renal (≥90% as inorganic phosphate and sodium). Fecal elimination is minimal (<5%) via unabsorbed phosphate.
Category C
Category C
Electrolyte Supplement
Electrolyte Supplement